# Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide

Study · id `cardio:ct-nct07220759` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07220759](<https://clinicaltrials.gov/study/NCT07220759>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07220759

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is active, not recruiting. It plans to enroll 330 participants.

## Technical summary

Registry record NCT07220759. Randomized; quadruple masking; primary purpose treatment. Start 2025-11-05 (actual); primary completion 2027-05-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 330 participants (planned count; ClinicalTrials.gov record NCT07220759, source copy `cardio:ctgov-nct07220759-2026-11-16`, retrieved 2026-11-18)
- Started: 2025-11-05 (actual) (ClinicalTrials.gov record NCT07220759, source copy `cardio:ctgov-nct07220759-2026-11-16`, retrieved 2026-11-18)
- Primary completion: 2027-05-12 (anticipated) (ClinicalTrials.gov record NCT07220759, source copy `cardio:ctgov-nct07220759-2026-11-16`, retrieved 2026-11-18)
- Completion: 2027-06-30 (anticipated) (ClinicalTrials.gov record NCT07220759, source copy `cardio:ctgov-nct07220759-2026-11-16`, retrieved 2026-11-18)
- Countries: United States; Argentina; Canada; Croatia; Czechia; Hungary; Romania; Slovakia; South Korea; Switzerland; United Kingdom (ClinicalTrials.gov record NCT07220759, source copy `cardio:ctgov-nct07220759-2026-11-16`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "ACTIVE\_NOT\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07220759-2026-11-16`, retrieved 2026-11-18)

## The registry's words

- Brief title: Weight Loss in People Living With Overweight or Obesity and Type 2 Diabetes Following Treatment With Cagrilintide
- Acronym: RENEW 2
- Condition: Overweight
- Condition: Obesity
- Condition: Type 2 Diabetes
- Intervention (Drug): Cagrilintide
- Intervention (Drug): Placebo (matched to Cagrilintide)
- Lead sponsor: Novo Nordisk A/S
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Novo Nordisk (`cardio:novo-nordisk`)

## Provenance

Content hash: 52d5ab968f0de845a676a6badd22f5efdd52af57aeffd25a7e23ae718971f731
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
